# Course Faculty, IAS–USA Staff, and Board of Directors

# Financial Relationships With Commercial Entities

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines** a **commercial interest** as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest." Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the Faculty Financial Disclosure Policy.

## 2020 IAS-USA National Virtual Course – November 12, 2020

| Course Presenters | |
|---|---|
| **Ann R. Falsey, MD**<br>Professor of Medicine<br>University of Rochester School of Medicine<br>Rochester, New York | Dr Falsey has served on the data and safety monitoring board for Novavax, Inc. and has received grants paid to her institution from Merck & Co, Inc., Sharpe and Dohme, Pfizer, Janssen Therapeutics, and BioFire. (Updated 11/01/20) |
| **Monica Gandhi, MD, MPH**<br>Professor of Medicine<br>Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine<br>University of California San Francisco<br>San Francisco, California | Dr Gandhi has no relevant financial affiliations to disclose. (Updated 09/10/20) |
| **Henry Masur, MD**<br>Clinical Professor of Medicine<br>George Washington University School of Medicine<br>Washington, District of Columbia | Dr Masur has no relevant financial affiliations to disclose. (Updated 11/02/20) |
| **Gregorio Millett, MPH**<br>Vice President and Director, Public Policy<br>amfAR, The Foundation for AIDS Research<br>Washington, District of Columbia | Mr Millett has received a grant from ViiV Healthcare and has received payment from Gilead Sciences Inc. and Merck & Co for to present research. (Updated 09/17/20) |
| **Michael Saag, MD**<br>Professor of Medicine<br>Jim Straley Chair in AIDS Research<br>Director, Center for AIDS Research<br>Associate Dean for Global Health, School of Medicine<br>University of Alabama at Birmingham<br>Birmingham, Alabama | Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20) |

| IAS–USA CME Planners and Reviewers | |
|---|---|
| **Henry Masur, MD** | Dr Masur has no relevant financial affiliations to disclose. (Updated 11/02/20) |
| **Michael Saag, MD** | Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20) |
| **Donna M. Jacobsen**<br>Executive Director/President<br>IAS–USA | *Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 10/21/20)* |

| IAS–USA Board of Directors |
|---|
| *The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information. |